Adenomatoid odontogenic tumor molecular pathogenesis: focusing on KRAS oncogenic mutations
DOI:
https://doi.org/10.5327/2525-5711.301Keywords:
Adenomatoid tumor, KRAS; Genetics, MAPK/ERK, Molecular pathologyAbstract
Adenomatoid odontogenic tumor is a rare benign odontogenic tumor, accounting for less than 10% of odontogenic tumors. It primarily affects young females and typically grows slowly, often in association with an unerupted permanent maxillary canine. Histologically, it contains rosette- or duct-like structures. A monoclonal tumor origin has been suggested and more recently KRAS mutations, particularly at codon 12, have been reported in a high proportion of cases. The MAPK/ERK pathway is activated in adenomatoid odontogenic tumor, even in KRAS wild-type cases, suggesting that other mechanisms may lead to the activation of this pathway. Considering that the tumor usually exhibits an indolent clinical course with almost no risk of recurrence after conservative surgical treatment, the value of targeted therapies is unclear. The rarity of adenomatoid odontogenic tumor limits large-scale studies, but future research may reveal additional mutations and their role on its pathogenesis.
References
Vargas PA, Gomes CC, Upadhyaya J, van Heerden WFP. Adenomatoid odontogenic tumour. In: World Health Organization Classification of Tumours Editorial Board. Head and neck tumours. Lyon: International Agency for Research on Cancer; 2024.
Chrcanovic BR, Gomez RS. Adenomatoid odontogenic tumor: an updated analysis of the cases reported in the literature. J Oral Pathol Med. 2019;48(1):10-6. https://doi.org/10.1111/jop.12783
Ernst LM, Quinn PD, Alawi F. Novel oral findings in Schimmelpenning syndrome. Am J Med Genet A. 2007;143A(8):881-3. https://doi.org/10.1002/ajmg.a.31663
Chaves RRM, Pinto Júnior AAC, Gomes CC, Castro WH, Gomez RS. Multiple adenomatoid odontogenic tumors in a patient with Schimmelpenning syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129(1):e12-e17. https://doi.org/10.1016/j.oooo.2019.06.006
Gomes CC. Recurrent driver mutations in benign tumors. Mutat Res Rev Mutat Res. 2022;789:108412. https://doi.org/10.1016/j.mrrev.2022.108412
Gomes CC, Sousa SF, Menezes GHF, Duarte AP, Pereira TSF, Moreira RG, et al. Recurrent KRAS G12V pathogenic mutation in adenomatoid odontogenic tumours. Oral Oncol. 2016;56:e3-5. https://doi.org/10.1016/j.oraloncology.2016.03.001
Coura BP, Bernardes VF, Sousa SF, França JA, Pereira NB, Pontes HAR, et al. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features. Mod Pathol. 2019;32(6)799-806. https://doi.org/10.1038/s41379-018-0194-4
Gomes CC, Oliveira CS, Castro WH, Lacerda JCT, Gomez RS. Clonal nature of odontogenic tumours. J Oral Pathol Med. 2009;38(4):397-400. https://doi.org/10.1111/j.1600-0714.2008.00744.x
Perdigão PF, Gomez RS, Pimenta FJGS, De Marco L. Ameloblastin gene (AMBN) mutations associated with epitelial odontogenic tumors. Oral Oncol. 2004;40(8):841-6. https://doi.org/10.1016/j.oraloncology.2004.03.004
Harnet JC, Pedeutour F, Raybaud H, Ambrosetti D, Fabas T, Lombardi T. Immunohistological features in adenomatoid odontogenic tumor: review of the literature and first expression and mutational analysis of β-catenin in the unusual lesion of the jaws. J Oral Maxillofac Surg. 2013;71(4):706-13. https://doi.org/10.1016/j.joms.2012.10.006
Shimura M, Nakashiro KI, Sawatani Y, Hasegawa T, Kamimura R, Izumi S et al. Whole exome sequencing of SMO, BRAF, PTCH1 and GNAS in odontogenic diseases. In Vivo. 2020;34(6)3233-40. https://doi.org/10.21873/invivo.12159
Bologna-Molina R, Ogawa I, Mosqueda-Taylor A, Takata T, Sánchez-Romero C, Villarroel-Dorrego M, et al. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors. Oral Dis. 2019;25(2)481-7. https://doi.org/10.1111/odi.12989
Xue J, Zhang W, Zhang J, Bai J, Zhang A, Guo X, et al. Adenoid ameloblastoma shares clinicopathologic, immunohistochemical, and molecular features with dentinogenic ghost cell tumor: a comparative analysis. Am J Surg Pathol. 2023;47(11):1274-84. https://doi.org/10.1097/PAS.0000000000002104
Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1):91. https://doi.org/10.1038/s41698-022-00334-z
Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029-38. https://doi.org/10.1007/s10555-020-09915-5
Haigis KM. KRAS Alleles: the devil is in the detail. Trends Cancer. 2017;3(10):686-97. https://doi.org/10.1016/j.trecan.2017.08.006
Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE. 2004;(250):RE13. https://doi.org/10.1126/stke.2502004re13
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Isadora Gomes, Carolina Gomes
This work is licensed under a Creative Commons Attribution 4.0 International License.
